PDCD1 and neoplasm: To investigate the sensitivity of various preclinical tumor models to immune checkpoint inhibitors, anti-PD-1 monoclonal antibody (mAb) was tested across 23 different syngeneic tumor mouse models on C57BL/6, BALB/c and DBA/2 genetic background mice (Fig. 1A).